Merck MRK, known as MSD outside the United States and Canada,
today announced data for its investigational Timothy grass sublingual
allergy immunotherapy tablet (MK-7243) from a study involving 1,501
North American adult and pediatric patients. Results showed that MK-7243
demonstrated significant improvement in Total Combined Score (TCS)
averaged over the entire grass pollen season (the primary endpoint),
which was the sum of the rhinoconjunctivitis daily symptom score (DSS)
and the daily medication score (DMS), compared to placebo. Researchers
will present findings at the American College of Allergy, Asthma &
Immunology Annual Scientific Meeting, Nov. 7-11, in Baltimore.
“Patients in this study who took the investigational Timothy grass
sublingual allergy immunotherapy tablet showed a
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in